CD8A and neoplasm: Instead of global metrics of diversity, the most informative variables in this study were the number of CD8+ clones at baseline with experimentally confirmed tumour reactivity, and the number of these dominant clones carried over in the TIL product for re-infusion, yielding a TIL product with a higher absolute number of tumour-reactive clones.